Cytorex - News

Weston, Florida Nov. 28, 2006

Title:	CYTOREX BIOSCIENCES GETS US PATENT ON IT'S ANTI-CANCER DRUG “CYTOREG®”.
Released by:	Cytorex Biosciences, Inc.
Release Date:	2006-11-28 21:46:09
Summary:	Cytorex Biosciences Inc. (Cytorex) announced today that it has been granted Patent No.7,141,251 by the United States Patent & Trademark Office titled: “Pharmacologically Active Strong Acid Solutions”.

For Immediate Release:

Prof. David Martucci, Cytorex President/CEO, and Inventor stated: "We are extremely excited to be granted the patent on this anti-cancer technology . Cytoreg® is a pharmacologically active low pH acidic mixture of which hydrofluoric acid (HF) is an active principal. Cytoreg® is used to treat several types of cancers such as solid tumors, blood cancers, and lymphomas. Cytoreg® is an innovative alternative to cancer treatments currently used".

Prof. David Martucci, President & CEO
Cytorex Biosciences, Inc.

According to Prof. Martucci "Cytoreg® will generate a paradigm shift in the way cancer is treated. In fact, Cytoreg® has the potential to replace chemotherapy, as it is a medical breakthrough".

The company's website outlines a list of Cytoreg® benefits:

Cytoreg® is a “smart drug”, with multiple mechanisms of action;

Cytoreg® reduces tumor mass and/or stops tumor growth or even destroys malignant cancer tumors;

Cytoreg® has proven to work faster than most chemotherapeutical agents;

Cytoreg® has not shown significant long-term side effects and life improvement for patients is substantial;

Cytoreg® is easy to produce and manufacturing costs are very low.

About Cytorex Biosciences, Inc.

Cytorex Biosciences, Inc. is a biotechnology company based in the United States, operating its business out of Weston, Florida. With its proprietary compound Cytoreg®, Cytorex Biosciences, Inc. intends to become a worldwide leading company in the fight against cancer. The company is currently seeking additional venture capital funding in order to complete the preclinical phase to be in position to start Clinical Trials in humans for the first indication: Glioblastoma Multiforme (GBM).

For more details:
Contact Information:
Carlos M. Garcia, MEng.
Director & COO | Cytorex Biosciences, Inc.
4474 Weston Road No. 108, Weston, FL 33331
TEL: 954-937-8519
MOBILE: 954-993-4941
FAX: 954-337-2249
cmgarcia@cytorex.com
Internet: www.cytorex.com

Cytorex Biosciences to present at the Southeast Venture Capital Investment Competition in Atlanta

Weston, Florida. March 2, 2006.

(Source: http://bioflorida.com/node/137)

Cytorex Biosciences, Inc., a Weston, Florida based Biotechnology company, has been invited to present at the Southeast Venture Capital Investment Competition (VCIC®), sponsored by the Dupree College of Management of the Georgia Institute of Technology. The event will be held on March 3, 2006 at the Huang Executive Education Wing.

This competition consists of teams of five students who will be given the role of venture capital firms. After reading the business plans of the participating companies, the student teams will have the opportunity to watch a fifteen minute live presentation of each company, and then they will perform due dilligence with a follow-up fifteen minute session of questions and answers. The evening of the event day, the teams will review the presenting companies and will make their investment decisions. The following day the teams will be presenting their investment choices to the panel of eight judges, all of which are active members of Venture Capital companies in the Southeast Region.

The VCIC® is the nation’s premiere strategy competition for venture–minded and entrepreneurial MBA students. This one–of–a–kind competition gives students from top business schools a real–world venture capitalist experience — student teams interact with real entrepreneurs from real companies with real business plans. Unlike other competitions where teams lock themselves away to mull over theoretical or historical scenarios, the VCIC® experience exposes students to a variety of activities that ultimately must be integrated into a cohesive investment strategy to be pitched to real venture capitalists. Many students hail the VCIC® as the most valuable learning experience of their MBA careers.

Brief History

In 1998, the technology boom was well under way, and business plan competitions began popping up at almost every business school. The Center for Entrepreneurial Studies at UNC’s Kenan–Flagler Business School was looking for a new twist on the old idea. What if students play the role of investors rather than entrepreneurs? What if real entrepreneurs who are pitching to real VCs pitch to students instead? Students could have the opportunity to evaluate numerous real business plans and share in the dreams of real entrepreneurs from the perspective of potential investors —what a great education for future entrepreneurs and future venture capitalists alike!

Thus was the genesis of the VCIC®. UNC, Duke, Virginia and Wake Forest participated in this new experiment in ’98, and it worked. Within two years, the VCIC went national, with four regional competitions and 27 schools. By 2002, all of the nation’s top business schools were regularly signing up, with many more knocking at the door. By 2005, two new wild card rounds had been added, bringing the number of schools participating to 40. VCIC is the only competition to regularly include teams from all top 20 business schools.

The year 2005 also marked the first international event for VCIC. London Business School held an internal VCIC and sent the winning team to the southeast region. Plans in 2006 include a new European VCIC, whose winners will join U.S. regional finalists at the VCIC Championship held annually in the University of North Carolina (Chappel Hill), Kenan-Flagler Business School. Dates for the 2006 finals are April 6-8.

While the VCIC expands internationally, it also grows at home. In 2005, a dozen schools held internal events for as many as 40 of their own students, meaning nearly 500 students worldwide were able to participate in this unique entrepreneurial educational experience. The last three VCIC championship teams started as victors at internal events.

About Cytorex Biosciences, Inc.

Cytorex Biosciences, Inc. (Cytorex) is a preclinical-stage biotechnology company developing therapeutic candidates primarily for the treatment of cancer. Cytoreg®, our patent pending lead drug candidate, is currently in preclinical testing for cancer, as well as in discovery and preclinical development for indications in diseases of immune origin. Cytorex’s objective is to market new compounds based on our expertise in formulation of low acidic compositions for use in treatment of disease. Cytorex has another compound in development called CytoregUNO™, which is in preclinical discovery and development for various forms of skin cancer (basal & squamous cell), and other dermatological indications.

For more information, please contact: Carlos M. Garcia, MEng., Director & COO of Cytorex Biosciences, Inc. (www.cytorex.com) at 954-993-4941 or by sending an email message to: cmgarcia@cytorex.com

SOUTH FLORIDA BUSINESS JOURNAL

Journal of Carcinogenesis publishes research report on Cytorex Biosciences, Inc. lead compound Cytoreg®

Cytoreg® inhibits growth and proliferation of human adenocarcinoma cells via induction of apoptosis

Weston, Florida.
January 14, 2006

Cytorex Biosciences, Inc. (Cytorex), a Florida based biotechnology company, announced today the publication in the January 2006 issue of the Journal of Carcinogenesis, of a research report related to in-vitro efficacy testing in cancer cell lines and normal cell lines, with Cytoreg®, their lead anti-cancer compound.

"Cytoreg® inhibits growth and proliferation of human adenocarcinoma cells via induction of apoptosis", was submitted for publication by James Kumi-Diaka, DVM, PhD (corresponding author), from Florida Atlantic University (FAU), and the other co-authors: Manzur Hassanhi, MD, PhD , professor of Immunology and Cancer Research Scientist, from the University of Zulia (Venezuela), Brown Jayaan (FAU), Kendra Merchant (FAU) , Carlos M Garcia (Cytorex), and William Jimenez (Cytorex).

Dr. James Kumi-Diaka and Dr. Manzur Hassanhi, authors of
the research report about Cytoreg® published in the
January 2006 edition of Journal of Carcinogenesis.

ABSTRACT

BACKGROUND: Cancer is one of the devastating neovascular diseases that incapacitate so many people the world over. Recent reports from the National Cancer Institute indicate some significant gain therapy and cancer management as seen in the increase in the 5-year survival rate over the past two decades. Although near-perfect cure rate have been reported in the early-stage disease, these data reveal high recurrence rate and serious side effects including second malignancies and fatalities. Most of the currently used anticancer agents are only effective against proliferating cancer cells. Thus attention has been focused on potential anti-cancer agents capable of killing cancer cells independent of the cell cycle state, to ensure effective elimination of most cancer cells. The objective of this study was to test the Chemosensitivity and potential mechanism of action of a novel cancer drug, Cytoreg®, in a panel of human cancer cells. Methods: the study was performed using a series of bioassays including Trypan blue exclusion, MTS Growth inhibition, LDH-cytotoxicity, TUNEL-Terminal, DNA fragmentation, Apoptosis Assay, and the Caspase protease CPP32 activity assays. Results: Cytoreg® induced significant dose- and time-dependent inhibition of growth in all the cells; with significant differences in Chemosensitivity (P <0.05) between the target cells, becoming more apparent at 48 hr exposure. Cytoreg® showed no significant effect on normal cells relative to the tumor cells. Growth inhibition in all the cells was due to induction of apoptosis at lower concentrations of Cytoreg® (>1:300). Cytoreg®-induced caspase protease-3 (CPP32) activation significantly and positively correlated with apoptosis induction and growth inhibition; thus implicating CPP32 as the principal death pathway in Cytoreg®-induced apoptosis. Conclusion: Cytoreg® exerted a dose-and time-dependent growth inhibitory effect in all the target cells through induction of apoptosis via the CPP32 death pathway, independent of hormonal sensitivity of the cells. The present data indicate that not only could CPP32 provide a potential target for regulation of Cytoreg®-induced apoptosis but also that Cytoreg® could play a significant role in chemotherapeutic regimen in many human malignant tumors.

“This is the first of several research reports about Cytoreg® we plan to submit during 2006 to peer-reviewed journals", said Dr. James Kumi-Diaka, Professor of Biology of cancer at Florida Atlantic University in Davie, Florida.

“Cytoreg® has great potential as an anti-cancer compound, and additional research has shown that this compound’s toxicity level is very low if compared with current approved chemotherapeutical agents”, indicated Dr. Manzur Hassanhi, Professor of Immunology and Cancer Research Scientist of the University of Zulia (Maracaibo-Venezuela).

Both Kumi-Diaka and Hasannhi, have lead since 2003 a multinational research team involved in the discovery of Cytoreg® as an anti-cancer agent.

According to Cytorex Vice-President & CFO, William Jimenez, who is also a co-author of this research report, "Cytoreg® is a therapeutic agent for cellular regulation, with antineoplastic properties which may also be used to fight immunological diseases. Cytoreg® constitutes a balanced mixture of strong and weak acids in an aqueous medium; resembling a buffer without using salts. Cytoreg® is transferred into a cellular system through ionic transport due to its low molecular weight, where each ion acts concurrently in cells, turning Cytoreg® into a highly efficient “smart-drug.” Cytoreg®’s numerous mechanisms of action are exerted through the cellular membrane".

A complete PDF version of the report is can be accessed through the Journal of Carcinogenesis web page:

http://www.carcinogenesis.com/content/pdf/1477-3163-5-1.pdf

For more information, please contact: Carlos M. Garcia, MEng., Director & COO of Cytorex Biosciences, Inc. at 954-993-4941 or by sending an email message to: cmgarcia@cytorex.com .